Update on models of pulmonary fibrosis therapy for preclinical drug research

Bibliography

• Hosenpud JD, Bennett LE, Keck BM, et al. Effect of diagnosis on survival benefit of lung transplantation for end-stage lung disease. Lancet 1998;351(9095):24-7
   PubMed Web of Science ®Google Scholar
• Williams T, Wilson JW. Challenges in pulmonary fibrosis: 7–Novel therapies and lung transplantation. Thorax 2008;63(3):277-84
   PubMed Web of Science ®Google Scholar
• Bouros D. Current classification of idiopathic interstitial pneumonias. Monaldi Arch Chest Dis 2000;55(6):450-4
   PubMedGoogle Scholar
• Flaherty KR, Andrei AC, Murray S, et al. Idiopathic pulmonary fibrosis: prognostic value of changes in physiology and six-minute-walk test. Am J Respir Crit Care Med 2006;174(7):803-9
   PubMed Web of Science ®Google Scholar
• American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med 2000;161(2 Pt 1):646-64
   PubMed Web of Science ®Google Scholar
• Bouros D, Antoniou KM. Current and future therapeutic approaches in idiopathic pulmonary fibrosis. Eur Respir J 2005;26(4):693-702
   PubMed Web of Science ®Google Scholar
• Collard HR, Moore BB, Flaherty KR, et al. Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2007;176(7):636-43
   PubMed Web of Science ®Google Scholar
• Selman M, King TE, Pardo A. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med 2001;134(2):136-51
   PubMed Web of Science ®Google Scholar
• Thannickal VJ, Toews GB, White ES, et al. Mechanisms of pulmonary fibrosis. Annu Rev Med 2004;55:395-417
   PubMed Web of Science ®Google Scholar
• Hinz B, Phan SH, Thannickal VJ, et al. The myofibroblast: one function, multiple origins. Am J Pathol 2007;170(6):1807-16
   PubMed Web of Science ®Google Scholar
• Moeller A, Gilpin SE, Ask K, et al. Circulating fibrocytes are an indicator of poor prognosis in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2009;179(7):588-94
   PubMed Web of Science ®Google Scholar
• Willis BC, Dubois RM, Borok Z. Epithelial origin of myofibroblasts during fibrosis in the lung. Proc Am Thorac Soc 2006;3(4):377-82
   PubMedGoogle Scholar
• Ask K, Martin GE, Kolb M, Gauldie J. Targeting genes for treatment in idiopathic pulmonary fibrosis: challenges and opportunities, promises and pitfalls. Proc Am Thorac Soc 2006;3(4):389-93
   PubMedGoogle Scholar
• Eickelberg O, Kohler E, Reichenberger F, et al. Extracellular matrix deposition by primary human lung fibroblasts in response to TGF-beta1 and TGF-beta3. Am J Physiol 1999;276(5 Pt 1):L814-24
   PubMed Web of Science ®Google Scholar
• Schonherr E, Hausser HJ. Extracellular matrix and cytokines: a functional unit. Dev Immunol 2000;7(2-4):89-101
   PubMedGoogle Scholar
• The drug-induced lung diseases. Available from: www.pneumotox.com [Accessed April 2009]
   Google Scholar
• Schirner M, Hoffmann J, Menrad A, Schneider MR. Antiangiogenic chemotherapeutic agents: characterization in comparison to their tumor growth inhibition in human renal cell carcinoma models. Clin Cancer Res 1998;4(5):1331-6
   PubMed Web of Science ®Google Scholar
• Sleijfer S. Bleomycin-induced pneumonitis. Chest 2001;120(2):617-24
   PubMed Web of Science ®Google Scholar
• Rossi S, Erasmus JJ, McAdams P, et al. Pulmonary drug-toxicity: radiologic and pathologic manifestations. Radiographics 2000;20:1245-59
   PubMed Web of Science ®Google Scholar
• Moore BB, Hogaboam CM. Murine models of pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 2008;294(2):L152-60
   PubMed Web of Science ®Google Scholar
• Kolb M, Bonniaud P, Galt T, et al. Differences in the fibrogenic response after transfer of active transforming growth factor-beta1 gene to lungs of “fibrosis-prone” and “fibrosis-resistant” mouse strains. Am J Respir Cell Mol Biol 2002;27(2):141-50
   PubMed Web of Science ®Google Scholar
• Kaminski N, Allard JD, Pittet JF, et al. Global analysis of gene expression in pulmonary fibrosis reveals distinct programs regulating lung inflammation and fibrosis. Proc Natl Acad Sci USA 2000;97(4):1778-83
   PubMed Web of Science ®Google Scholar
• Chua F, Gauldie J, Laurent GJ. Pulmonary Fibrosis: searching for model answers. Am J Respir Cell Mol Biol 2005;33(1):9-13
   PubMed Web of Science ®Google Scholar
• Moeller A, Ask K, Warburton D, et al. The bleomycin animal model: a useful tool to investigate treatment options for idiopathic pulmonary fibrosis? Int J Biochem Cell Biol 2008;40(3):362-82
   PubMed Web of Science ®Google Scholar
• Izbicki G, Segel MJ, Christensen TG, et al. Time course of bleomycin-induced lung fibrosis. Int J Exp Pathol 2002;83(3):111-9
   PubMed Web of Science ®Google Scholar
• Lee CH, Jang YS, Her SJ, et al. Nordihydroguaiaretic acid, an antioxidant, inhibits transforming growth factor-beta activity through the inhibition of Smad signaling pathway. Exp Cell Res 2003;289(2):335-41
   PubMed Web of Science ®Google Scholar
• Kolb M, Margetts PJ, Anthony DC, et al. Transient expression of IL-1beta induces acute lung injury and chronic repair leading to pulmonary fibrosis. J Clin Invest 2001;107(12):1529-36
   PubMed Web of Science ®Google Scholar
• Sime PJ, Xing Z, Graham FL, et al. Adenovector-mediated gene transfer of active transforming growth factor-beta1 induces prolonged severe fibrosis in rat lung. J Clin Invest 1997;100(4):768-76
   PubMed Web of Science ®Google Scholar
• Christensen PJ, Goodman RE, Pastoriza L, et al. Induction of lung fibrosis in the mouse by intratracheal instillation of fluorescein isothiocyanate is not T-cell-dependent. Am J Pathol 1999;155(5):1773-9
   PubMed Web of Science ®Google Scholar
• Roberts SN, Howie SE, Wallace WA, et al. A novel model for human interstitial lung disease: hapten-driven lung fibrosis in rodents. J Pathol 1995;176(3):309-18
   PubMed Web of Science ®Google Scholar
• Lasky JA, Brody AR. Interstitial fibrosis and growth factors. Environ Health Perspect 2000;108(Suppl 4):751-62
   PubMed Web of Science ®Google Scholar
• Adamson IY. Pulmonary toxicity of bleomycin. Environ Health Perspect 1976;16:119-25
   PubMed Web of Science ®Google Scholar
• Ask K, Labiris R, Farkas L, et al. Comparison between conventional and “clinical” assessment of experimental lung fibrosis. J Transl Med 2008;6:16
   PubMedGoogle Scholar
• Giri SN, Leonard S, Shi X, et al. Effects of pirfenidone on the generation of reactive oxygen species in vitro. J Environ Pathol Toxicol Oncol 1999;18(3):169-77
   PubMedGoogle Scholar
• Antoniu SA. Pirfenidone for the treatment of idiopathic pulmonary fibrosis. Expert Opin Investig Drugs 2006;15(7):823-8
   PubMed Web of Science ®Google Scholar
• Iyer SN, Wild JS, Schiedt MJ, et al. Dietary intake of pirfenidone ameliorates bleomycin-induced lung fibrosis in hamsters. J Lab Clin Med 1995;125(6):779-85
   PubMed Web of Science ®Google Scholar
• Schelegle ES, Mansoor JK, Giri S. Pirfenidone attenuates bleomycin-induced changes in pulmonary functions in hamsters. Proc Soc Exp Biol Med 1997;216(3):392-7
   PubMed Web of Science ®Google Scholar
• Gurujeyalakshmi G, Hollinger MA, Giri SN. Pirfenidone inhibits PDGF isoforms in bleomycin hamster model of lung fibrosis at the translational level. Am J Physiol Lung Cell Mol Physiol 1999;276(2):L311-8
   PubMed Web of Science ®Google Scholar
• Iyer SN, Gurujeyalakshmi G, Giri SN. Effects of pirfenidone on transforming growth factor-beta gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. J Pharmacol Exp Ther 1999;291(1):367-73
   PubMed Web of Science ®Google Scholar
• Iyer SN, Gurujeyalakshmi G, Giri SN. Effects of pirfenidone on procollagen gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. J Pharmacol Exp Ther 1999;289(1):211-8
   PubMed Web of Science ®Google Scholar
• Kakugawa T, Mukae H, Hayashi T, et al. Pirfenidone attenuates expression of HSP47 in murine bleomycin-induced pulmonary fibrosis. Eur Respir J 2004;24(1):57-65
   PubMed Web of Science ®Google Scholar
• Oku H, Shimizu T, Kawabata T, et al. Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis. Eur J Pharmacol 2008;590(1-3):400-8
   PubMed Web of Science ®Google Scholar
• Available from: www.clinicaltrials.gov
   Google Scholar
• Walter N, Collard HR, King TE Jr. Current perspectives on the treatment of idiopathic pulmonary fibrosis. Proc Am Thorac Soc 2006;3(4):330-8
   PubMedGoogle Scholar
• Noble PAC, Bradford W, Costabel U, et al. The CAPACITY (CAP) Trials: Randomized, Double-Blind, Placebo-Controlled, Phase III Trials of Pirfenidone (PFD) in Patients with Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med 2009;179:A1129
   Google Scholar
• Cattermole GN. Oral N-acetylcysteine for acute paracetamol poisoning. Emerg Med J 2007;24(12):866
   PubMed Web of Science ®Google Scholar
• Stey C, Steurer J, Bachmann S, et al. The effect of oral N-acetylcysteine in chronic bronchitis: a quantitative systematic review. Eur Respir J 2000;16(2):253-62
   PubMed Web of Science ®Google Scholar
• Pardo A, Ruiz V, Arreola JL, et al. Bleomycin-induced pulmonary fibrosis is attenuated in gamma-glutamyl transpeptidase-deficient mice. Am J Respir Crit Care Med 2003;167(6):925-32
   PubMed Web of Science ®Google Scholar
• Day RM, Suzuki YJ, Lum JM, et al. Bleomycin upregulates expression of gamma-glutamylcysteine synthetase in pulmonary artery endothelial cells. Am J Physiol Lung Cell Mol Physiol 2002;282(6):L1349-57
   PubMed Web of Science ®Google Scholar
• Giri SN, Hyde DM, Schiedt MJ. Effects of repeated administration of N-acetyl-L-cysteine on sulfhydryl levels of different tissues and bleomycin-induced lung fibrosis in hamsters. J Lab Clin Med 1988;111(6):715-24
   PubMed Web of Science ®Google Scholar
• Shahzeidi S, Sarnstrand B, Jeffery PK, et al. Oral N-acetylcysteine reduces bleomycin-induced collagen deposition in the lungs of mice. Eur Respir J 1991;4(7):845-52
   PubMed Web of Science ®Google Scholar
• Hagiwara SI, Ishii Y, Kitamura S. Aerosolized administration of N-acetylcysteine attenuates lung fibrosis induced by bleomycin in mice. Am J Respir Crit Care Med 2000;162(1):225-31
   PubMed Web of Science ®Google Scholar
• Mata M, Ruiz A, Cerda M, et al. Oral N-acetylcysteine reduces bleomycin-induced lung damage and mucin Muc5ac expression in rats. Eur Respir J 2003;22(6):900-5
   PubMed Web of Science ®Google Scholar
• Demedts M, Behr J, Buhl R, et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2005;353(21):2229-42
   PubMed Web of Science ®Google Scholar
• Schroder K, Hertzog PJ, Ravasi T, Hume DA. Interferon-{gamma}: an overview of signals, mechanisms and functions. J Leukoc Biol 2004;75(2):163-89
   PubMed Web of Science ®Google Scholar
• Bouros D, Antoniou KM, Tzouvelekis A, Siafakas NM. Interferon-gamma 1b for the treatment of idiopathic pulmonary fibrosis. Expert Opin Biol Ther 2006;6(10):1051-60
   PubMed Web of Science ®Google Scholar
• Tanaka K, Sano K, Yuba K, et al. Inhibition of induction of myofibroblasts by interferon gamma in a human fibroblast cell line. Int Immunopharmacol 2003;3(9):1273-80
   PubMed Web of Science ®Google Scholar
• Hyde DM, Henderson TS, Giri SN, et al. Effect of murine gamma interferon on the cellular responses to bleomycin in mice. Exp Lung Res 1988;14(5):687-704
   PubMed Web of Science ®Google Scholar
• Gurujeyalakshmi G, Giri SN. Molecular mechanisms of antifibrotic effect of interferon gamma in bleomycin-mouse model of lung fibrosis: downregulation of TGF-beta and procollagen I and III gene expression. Exp Lung Res 1995;21(5):791-808
   PubMed Web of Science ®Google Scholar
• Segel MJ, Izbicki G, Cohen PY, et al. Role of interferon-gamma in the evolution of murine bleomycin lung fibrosis. Am J Physiol Lung Cell Mol Physiol 2003;285(6):L1255-62
   PubMed Web of Science ®Google Scholar
• Chen ES, Greenlee BM, Wills-Karp M, Moller DR. Attenuation of lung inflammation and fibrosis in interferon-gamma-deficient mice after intratracheal bleomycin. Am J Respir Cell Mol Biol 2001;24(5):545-55
   PubMed Web of Science ®Google Scholar
• Antoniou KM, Nicholson AG, Dimadi M, et al. Long-term clinical effects of interferon gamma-1b and colchicine in idiopathic pulmonary fibrosis. Eur Respir J 2006;28(3):496-504
   PubMed Web of Science ®Google Scholar
• Raghu G, Brown KK, Bradford WZ, et al. A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med 2004;350(2):125-33
   PubMed Web of Science ®Google Scholar
• Study in Idiopathic Pulmonary Fibrosis terminated early 2007. Available from: http://www.medscape.com/viewarticle/ 553501Interferon gamma-1b
   Google Scholar
• Jain M, Varga J. Bosentan for the treatment of systemic sclerosis-associated pulmonary arterial hypertension, pulmonary fibrosis and digital ulcers. Expert Opin Pharmacother 2006;7(11):1487-501
   PubMed Web of Science ®Google Scholar
• Park SH, Saleh D, Giaid A, Michel RP. Increased endothelin-1 in bleomycin-induced pulmonary fibrosis and the effect of an endothelin receptor antagonist. Am J Respir Crit Care Med 1997;156(2 Pt 1):600-8
   PubMed Web of Science ®Google Scholar
• Mutsaers SE, Foster ML, Chambers RC, et al. Increased endothelin-1 and its localization during the development of bleomycin-induced pulmonary fibrosis in rats. Am J Respir Cell Mol Biol 1998;18(5):611-9
   PubMed Web of Science ®Google Scholar
• Saleh D, Furukawa K, Tsao MS, et al. Elevated expression of endothelin-1 and endothelin-converting enzyme-1 in idiopathic pulmonary fibrosis: possible involvement of proinflammatory cytokines. Am J Respir Cell Mol Biol 1997;16(2):187-93
   PubMed Web of Science ®Google Scholar
• Mutsaers SE, Marshall RP, Goldsack NR, et al. Effect of endothelin receptor antagonists (BQ-485, Ro 47-0203) on collagen deposition during the development of bleomycin-induced pulmonary fibrosis in rats. Pulm Pharmacol Ther 1998;11(2-3):221-5
   PubMed Web of Science ®Google Scholar
• King TE Jr, Behr J, Brown KK, et al. BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2008;177(1):75-81
   PubMed Web of Science ®Google Scholar